ReviewCancers2016
Updates in Therapy for Advanced Melanoma.
Review in Cancers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- α-Mangostin Suppresses Melanoma Growth, Migration, and Invasion and Potentiates the Anti-tumor Effect of Chemotherapy.International journal of medical sciences · 2023Article
- Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeutics.Medicinal research reviews · 2022Review
- Article
- The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma.Molecular oncology · 2022Review
- Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.Frontiers in immunology · 2022Article
- Anti-cancer effect of gallic acid in presence of low level laser irradiation: ROS production and induction of apoptosis and ferroptosis.Cancer cell international · 2020Article
- Review
- The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface.BMC pregnancy and childbirth · 2019Article
- Cirsiliol Suppressed Epithelial to Mesenchymal Transition in B16F10 Malignant Melanoma Cells through Alteration of the PI3K/Akt/NF-κB Signaling Pathway.International journal of molecular sciences · 2019Article
- Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma.Frontiers in pharmacology · 2019Article
- Article
- Long non-coding RNAs in melanoma.Cell proliferation · 2018Review
- Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients.Oncotarget · 2017Article
- Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.Journal of cancer research and clinical oncology · 2017Article
- Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis.Clinical, cosmetic and investigational dermatology · 2017Review
- FOXC1 promotes melanoma by activating MST1R/PI3K/AKT.Oncotarget · 2016Article
- IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process.Oncotarget · 2016Article
- Introducing MARCo: Histoserological Findings of a Multi-Organic Paraneoplastic Syndrome in Cutaneous Melanoma Patients.Dermatology and therapy · 2016Article
- [Anorectal malignant melanoma : Treatment recommendations].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2016Review
- Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.ESMO open · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma is one of the most aggressive forms of skin cancer, and is correlated with a large proportion of skin cancer-related deaths. Therapy for cutaneous melanoma has advanced greatly through careful identification of therapeutic targets and the development of novel immunotherapeutic approaches. The identification of BRAF as well as other driver mutations, have allowed for a specialized approach to treatment. In addition, immune checkpoint inhibition has dramatically changed the treatment landscape over the past 5-10 years. The successful targeting of CTLA-4, as well as PD-1/PD-L1, has been translated into meaningful clinical benefit for patients, with multiple other potential agents in development. Systemic therapy for cutaneous melanoma is becoming more nuanced and often takes a multifaceted strategy. This review aims to discuss the benefits and limitations of current therapies in systemic melanoma treatment as well as areas of future development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.